Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
121 hedge funds and large institutions have $106M invested in Acorda Therapeutics in 2019 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 40 increasing their positions, 42 reducing their positions, and 44 closing their positions.
5% more call options, than puts
Call options by funds: $665K | Put options by funds: $633K
5% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 42
20% less funds holding
Funds holding: 151 → 121 (-30)
33% less capital invested
Capital invested by funds: $157M → $106M (-$51.7M)
68% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.74M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.46M |
| 3 |
Two Sigma Investments
New York
|
+$892K |
| 4 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
+$884K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$842K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$7.96M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$6.41M |
| 3 |
FAM
Fred Alger Management
New York
|
-$2.29M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.96M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.58M |
ACOR Hedge Fund Activity: Q4 2019 in Review
121 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q4 2019, worth a combined $106M — down 33% from $157M a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of ACOR and 14 opened new positions — a net loss of 30 holders — while 42 trimmed existing stakes and 40 added.
The largest buyer was Point72 Asset Management, adding an estimated $7.74M. The largest seller was Scopia Capital Management, exiting entirely with an estimated $7.96M sold.
- 121 institutional investors held Acorda Therapeutics (ACOR) as of Q4 2019, down from 151 in Q3 2019.
- Funds reported $106M of Acorda Therapeutics stock for Q4 2019, down 33% quarter-over-quarter.
- 14 funds opened new Acorda Therapeutics positions in Q4 2019 and 44 closed out, a net change of -30 holders.
- The largest Acorda Therapeutics buyer in Q4 2019 was Point72 Asset Management, an estimated $7.74M added.
- The largest Acorda Therapeutics seller in Q4 2019 was Scopia Capital Management, an estimated $7.96M sold.
Based on aggregated 13F filings for Q4 2019.